
Please try another search
Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-protein inhibitor for the treatment of metastatic cancer; PHI-401, an anaplastic lymphoma kinase (ALK) protein inhibitor; and PHI-501 a pan-RAF/DDRs inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Lim Jeong-muk | - | - | Member of the Advisory Board |
Lee seong Kwang | - | - | Member of the Advisory Board |
Sim Tae-bo | - | - | Member of the Advisory Board |
Donald Small | - | - | Member of the Advisory Board |
Jeong Hyeok Yoon | 61 | 2023 | CEO & Director |
JongCheol Chae | 56 | - | CSO & Executive Director |
Sung Won Moon | 50 | 2022 | CFO & Executive Director |
Ky Youb Nam | 53 | 2021 | CTO & Director |
SangBok Lee | 63 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review